中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

不确定期慢性HBV感染者应积极抗病毒治疗

王静月 黄缘

王静月,黄缘. 不确定期慢性HBV感染者应积极抗病毒治疗[J]. 临床肝胆病杂志, 2021, 37(11): 2541-2542. DOI: 10.3969/j.issn.1001-5256.2021.11.008
引用本文: 王静月,黄缘. 不确定期慢性HBV感染者应积极抗病毒治疗[J]. 临床肝胆病杂志, 2021, 37(11): 2541-2542. DOI: 10.3969/j.issn.1001-5256.2021.11.008
WANG JY, HUANG Y. Patients in the indeterminate phase of chronic hepatitis B virus infection should receive active antiviral therapy [J]. J Clin Hepatol, 2021, 37(11): 2541-2542. DOI: 10.3969/j.issn.1001-5256.2021.11.008
Citation: WANG JY, HUANG Y. Patients in the indeterminate phase of chronic hepatitis B virus infection should receive active antiviral therapy [J]. J Clin Hepatol, 2021, 37(11): 2541-2542. DOI: 10.3969/j.issn.1001-5256.2021.11.008

不确定期慢性HBV感染者应积极抗病毒治疗

DOI: 10.3969/j.issn.1001-5256.2021.11.008
详细信息
    通讯作者:

    黄缘,huangy9815@163.com

  • 中图分类号: R512.62

Patients in the indeterminate phase of chronic hepatitis B virus infection should receive active antiviral therapy

  • [1] HUANG DQ, LI X, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.01.019.[Online ahead of print]
    [2] SPRADLING PR, XING J, RUPP LB, et al. Distribution of disease phase, treatment prescription and severe liver disease among 1598 patients with chronic hepatitis B in the Chronic Hepatitis Cohort Study, 2006-2013[J]. Aliment Pharmacol Ther, 2016, 44(10): 1080-1089. DOI: 10.1111/apt.13802.
    [3] GHANY MG, WAHED A, FELD JJ, et al. Indeterminant phenotypes of HBeAg-negtive chronic hepatitis B and predictors of transition to inactive or active disease: Outcomes of a prospective North Anerican Cohort[C]. AASLD 2020: Abstract (poster 764).
    [4] YAO K, LIU J, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28(7): 1025-1033. DOI: 10.1111/jvh.13511.
    [5] BONACCI M, LENS S, MARIÑO Z, et al. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone[J]. Aliment Pharmacol Ther, 2018, 47(10): 1397-1408. DOI: 10.1111/apt.14613.
    [6] TESTONI B, LEBOSSÉ F, SCHOLTES C, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients[J]. J Hepatol, 2019, 70(4): 615-625. DOI: 10.1016/j.jhep.2018.11.030.
    [7] CHEN EQ, WANG ML, TAO YC, et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA[J]. J Viral Hepat, 2019, 26(5): 586-595. DOI: 10.1111/jvh.13061.
    [8] LOGGI E, VUKOTIC R, CONTI F, et al. Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B[J]. J Viral Hepat, 2019, 26(5): 568-575. DOI: 10.1111/jvh.13054.
    [9] BRUNETTO MR, CAREY I, MAASOUMY B, et al. Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis[J]. Aliment Pharmacol Ther, 2021, 53(6): 733-744. DOI: 10.1111/apt.16258.
    [10] DUAN M, CHI X, XIAO H, et al. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B[J]. Hepatol Int, 2021, 15(2): 318-327. DOI: 10.1007/s12072-021-10153-2.
  • 加载中
计量
  • 文章访问数:  84
  • HTML全文浏览量:  5
  • PDF下载量:  54
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-08-30
  • 录用日期:  2021-08-30
  • 出版日期:  2021-11-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回